Carbapenem therapy for bacteremia due to extended-spectrum-β- lactamase-producing Escherichia coli or Klebsiella pneumoniae: Implications of ertapenem susceptibility

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 2888-2893

  Lee, Nan Yao ^a   Lee, Ching Chi ^a   Huang, Wei Han ^b   Tsui, Ko Chung ^c,d   Hsueh, Po Ren ^b   Ko, Wen Chien ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM;

AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; DISEASE SEVERITY; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HOSPITAL INFECTION; HUMAN; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SEPSIS; SURVIVOR; TAIWAN; TREATMENT OUTCOME; UNIVARIATE ANALYSIS;

ADULT; BACTEREMIA; BETA-LACTAMS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; IMIPENEM; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES; THIENAMYCINS; YOUNG ADULT;

EID: 84861132451     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06301-11     Document Type: Article

References (26)

1. Bradford PA. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951. (Pubitemid 32979636)
2. Chia JH, et al. 2009. Emergence of carbapenem-resistant Escherichia coli in Taiwan: resistance due to combined CMY-2 production and porin deficiency. J. Chemother. 21:621- 626.
3. Chow JW, Yu VL. 1999. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int. J. Antimicrob. Agents 11:7-12. (Pubitemid 29067411)
4. Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing, 21st informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Elliott E, et al. 2006. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended- spectrum beta-lactamase. Clin. Infect. Dis. 42:e95-e98.
7. European Committee on Antimicrobial Susceptibility Testing. 2011. Clinical breakpoint tables v 1.3. European Committee on Antimicrobial Susceptibility Testing, London, United Kingdom. http://www.eucast.org/eucast- susceptibility-testing/breakpoints/. Accessed 21 February 2012.
8. Falagas ME, Karageorgopoulos DE. 2009. Extended-spectrum beta-lactamase-producing organisms. J. Hosp. Infect. 73:345-354.
9. Huang SS, Lee MH, Leu HS. 2006. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella. J. Microbiol. Immunol. Infect. 39:496-502.
10. Kahlmeter G. 2008. Breakpoints for intravenously used cephalosporins in Enterobacteriaceae-EUCAST and CLSI breakpoints. Clin. Microbiol. Infect. 14(Suppl. 1):169-174. (Pubitemid 350269198)
11. Kang CI, et al. 2004. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob. Agents Chemother. 48:4574-4581.
12. McCabe W, Jackson GG. 1962. Gram-negative bacteremia. I. Etiology and ecology. Arch. Intern. Med. 110:847-855.
13. Paterson DL. 2000. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum betalactamases (ESBLs). Clin. Microbiol. Infect. 6:460-463. (Pubitemid 34966064)
14. Paterson DL. 2006. Resistance in gram-negative bacteria: Enterobacteriaceae. Am. J. Med. 119:S20-S28.
15. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686.
16. Paterson DL, et al. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin. Infect. Dis. 39:31-37. (Pubitemid 38879546)
17. Perez F, Endimiani A, Hujer KM, Bonomo RA. 2007. The continuing challenge of ESBLs. Curr. Opin. Pharmacol. 7:459-469. (Pubitemid 47560222)
18. Perrott J, Mabasa VH, Ensom MH. 2010. Comparing outcomes of meropenem administration strategies based on pharmacokinetic and pharmacodynamic principles: a qualitative systematic review. Ann. Pharmacother. 44:557-564.
19. Ramphal R, Ambrose PG. 2006. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin. Infect. Dis. 42(Suppl. 4):S164-S172.
20. Rossi F, et al. 2006. In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intraabdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends). J. Antimicrob. Chemother. 58:205-210. (Pubitemid 44295010)
21. Schwaber MJ, Carmeli Y. 2007. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J. Antimicrob. Chemother. 60:913-920. (Pubitemid 47617735)
22. Tenover FC, et al. 2006. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg. Infect. Dis. 12: 1209-1213.
23. Tumbarello M, et al. 2007. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamaseproducing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 51:1987-1994. (Pubitemid 46903084)
24. Woodford N, et al. 2007. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int. J. Antimicrob. Agents 29:456-459. (Pubitemid 46349596)
25. Yan JJ, Wu JJ, Lee CC, Ko WC, Yang FC. 2010. Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007. Eur. J. Clin. Microbiol. Infect. Dis. 29:1417-1425.
26. Yu WL, Chuang YC, Walther-Rasmussen J. 2006. Extended-spectrum beta-lactamases in Taiwan: epidemiology, detection, treatment and infection control. J. Microbiol. Immunol. Infect. 39:264 -277.